Regulatory
Unlicensed Sublingual Semaglutide Offered to UK Doctors, Drawing a Novo Nordisk Warning
A US compounding group is marketing an under-the-tongue, unapproved version of the weight-loss drug to private UK clinics — a practice Novo Nordisk says risks patient safety.